Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Parallel Group Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP).

NCT00441090 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00441090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00441090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Parallel Group Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP).
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
June 30, 2009
Enrollment
64 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

chronic idiopathic thrombocytopenic purpura, purpura, thrombocytopenic, idiopathic